ev-103: neoadjuvant enfortumab vedotin in cis-ineligible mibc
Published 2 years ago • 78 plays • Length 2:09Download video MP4
Download video MP3
Similar videos
-
1:24
ev-103 cohort h: neoadjuvant enfortumab vedotin monotherapy in cisplatin-ineligible mibc
-
2:20
ev-103 cohort k: enfortumab vedotin /- pembro in untreated cis-ineligible patients with muc
-
1:08
the future of enfortumab vedotin in different stages bladder cancer
-
2:10
initial ev-103 results: enfortumab vedotin plus pembrolizumab for urothelial carcinoma
-
2:43
ev-103: ev with pembrolizumab in cisplatin-ineligible urothelial carcinoma
-
0:33
phase iii volga: durvalumab tremelimumab enfortumab vedotin for neoadjuvant mibc
-
13:47
ev-103: enfortumab vedotin and pembrolizumab in urothelial carcinoma
-
3:07
enfortumab vedotin in urothelial cancer
-
2:26
niagara: perioperative durvalumab with neoadjuvant chemotherapy in mibc
-
0:45
prof. siefker-radtke on the ev-103 trial in bladder cancer
-
2:58
ev-201: enfortumab vedotin for cisplatin-ineligible bladder cancer
-
3:20
latest ev-103 update further supports enfortumab for untreated advanced uc | jonathan rosenberg
-
3:06
how effective are adcs in treating metastatic urothelial cancer?
-
0:35
ev-302: 1l enfortumab vedotin in combination with pembrolizumab
-
6:01
ev-201, ev-301 and unite: enfortumab vedotin in advanced urothelial cancer
-
1:24
dr. sonpavde on neoadjuvant immunotherapy in bladder cancer
-
1:03
one to watch: keynote-866, perioperative pembro with neoadjuvant chemo in mibc
-
1:32
24-month findings from ev-301: enfortumab vedotin vs chemotherapy in previously treated advanced uc
-
4:45
pre0807: neoadjuvant nivolumab/lirilumab in cisplatin ineligible patients with mibc